About Meridian Medical Technologies™, Inc.

Emergency auto-injector drug delivery systems Meridian Medical Technologies™, Inc., has more than 50 years of experience creating specialized products for emergency responders and military personnel around the globe. Meridian's antidotes are stocked by the U.S. Department of Defense, the U.S. Department of Homeland Security, emergency medical services personnel, and more than 30 nations around the world. Designed to meet the unique needs of patients in emergency situations, Meridian's auto-injectors allow for rapid administration of a specific dose of medication(s) and are appropriate for use in the prehospital setting.

Meridian became a part of Pfizer's Established Products business unit in March 2011, when Pfizer completed its acquisition of King Pharmaceuticals®, Inc., Meridian's former parent company. Meridian's executive offices are located in Columbia, Maryland.

For more information, please call 1-800-638-8093 or visit MeridianMeds.com.



Indication
CYANOKIT® (hydroxocobalamin for injection) 5 g for intravenous infusion is indicated for the treatment of known or suspected cyanide poisoning. If clinical suspicion of cyanide poisoning is high, CYANOKIT® should be administered without delay.

Important Safety Information
Cyanide poisoning may result from inhalation, ingestion, or dermal exposure. Prior to administration of CYANOKIT®, smoke-inhalation victims should be assessed for: exposure to fire or smoke in an enclosed area; presence of soot around the mouth, nose, or oropharynx, and altered mental status. In addition to CYANOKIT®, treatment of cyanide poisoning must include immediate attention to airway patency, adequacy of oxygenation and hydration, cardiovascular support, and management of any seizure activity.

Use caution in the management of patients with known anaphylactic reactions to hydroxocobalamin or cyanocobalamin. Allergic reactions may include: anaphylaxis, chest tightness, edema, urticaria, pruritus, dyspnea, rash, and angioneurotic edema. Substantial increases in blood pressure may occur following CYANOKIT® therapy. Usage may interfere with some clinical laboratory evaluations. Also, because of its deep red color, hydroxocobalamin may cause hemodialysis machines to shut down due to an erroneous detection of a "blood leak." This should be considered before hemodialysis is initiated in patients treated with hydroxocobalamin. Due to potential photosensitivity, patients should avoid direct sun until erythema resolves.

CYANOKIT® is Pregnancy Category C and should be used during pregnancy only if the potential benefit justifies the potential risk. Safety and effectiveness of CYANOKIT® have not been established in pediatric patients. The most common adverse reactions (>5%) are transient and include chromaturia, erythema, rash (predominantly acneiform), increased blood pressure, nausea, headache, decreased lymphocyte percentage, and injection site reactions.

Please see single 5-g vial full Prescribing Information. Please see two 2.5-g vial full Prescribing Information.

DISCLAIMER
This Web site is intended only for First Responders and Healthcare Professionals and is subject to all applicable US laws. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.